The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.